Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Dow
AstraZeneca
Colorcon
Express Scripts

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Litigation Details for ASTRAZENECA AB v. HANMI USA, INC. (D.N.J. 2011)

See Plans and Pricing

« Back to Dashboard

ASTRAZENECA AB v. HANMI USA, INC. (D.N.J. 2011)

Docket   Start Trial Date Filed 2011-02-09
Court District Court, D. New Jersey Date Terminated 2013-06-03
Cause 35:145 Patent Infringement Assigned To Joel A. Pisano
Jury Demand None Referred To Tonianne J. Bongiovanni
Parties AKTIEBOLAGET HASSLE; ASTRAZENECA AB; ASTRAZENECA LP; HANMI FINE CHEMICAL CO., LTD; HANMI HOLDINGS CO., LTD.; HANMI PHARMACEUTICAL CO., LTD.; HANMI USA, INC.; KBI INC.; KBI-E INC.
Patents 5,714,504
Attorneys ALLYN ZISSEL LITE; ARNOLD B. CALMANN; JEFFREY S. SOOS; JOHN EDMUND FLAHERTY; JONATHAN M.H. SHORT; MAYRA VELEZ TARANTINO; MICHAEL E. PATUNAS
Link to Docket External link to docket
Small Molecule Drugs cited in ASTRAZENECA AB v. HANMI USA, INC.
The small molecule drugs covered by the patent cited in this case are   Start Trial ,   Start Trial , and   Start Trial .

Details for ASTRAZENECA AB v. HANMI USA, INC. (D.N.J. 2011)

Date Filed Document No. Description Snippet Link To Document
2013-05-16 326 FDA that U.S. Patent Nos. 5,714,504 (“the ’504 patent”) and 5,877,192 (“the ’ 192 patent”) are invalid…omeprazole in claims 1 and 6 of U.S. Patent No. 5,714,504 (“the ’504 patent”) and the term “pharmaceutically…name NEXIUM®. IV. The Patents-In-Suit A. The ’504 Patent 23. . The ’504 patent issued to Astra Aktiebolaget…VIII. Hanmi’s Patents 52. Hanmi obtained U.S. Patent No. 7,576,219 B2 (“the ’219 patent”), entitled Crystalline…AstraZeneca's '974 Patent 56. U.S. Patent No. 4,738,974 ("the '974 patent") issued on April External link to document
2013-06-03 338 AstraZeneca’slU.S. Patent Nos. 5,714,504 and 5,877,192 (the “AstraZeneca Patents”) are all enforceable….S. Pate it No. 5,714,504 and “pharmaceutically acceptable salt” of the U.S. Patent No. 5,877,192, as…Hanmi Product does not infringe the AstraZeneca Patents under the provisions of 35 U.S.C. § 271. 6. Compliance… 2011 3 June 2013 3:11-cv-00760 830 Patent None District Court, D. New Jersey External link to document
2013-08-20 347 Exhibit B is a true and correct copy of U.S. Patent No. 5,714,504. 5. Attached as Exhibit C is a …excerpts from the File History of U.S. Patent No. 5,714,504, bearing Bates numbers HAN0039508-HAN0040299… 2011 3 June 2013 3:11-cv-00760 830 Patent None District Court, D. New Jersey External link to document
2013-09-27 378 U.S Patent No. 5,714,504 (the “ ‘504 patent”) and U.S. Patent No. 5,877,192 (the “ ‘192 patent”) based…a number of claim terms from the ‘504 patent and the ‘192 patent that were in dispute between the parties…Abstract of the ‘504 patent specification, which describes the subject matter of the patent as follows: …Judge. Presently before the Court in this patent infringement action is a motion by plaintiffs …strontium product before the expiration of the patents. On December 12, 2012, the Court issued a claim External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
McKesson
Baxter
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.